What challenges are associated with value-based oncology care and how can these be overcome? Read out latest interview feature to find out >>> bit.ly/4cK78di

Discover the strides being made to unravel the complexities of brain tumors in our interview with Karen Noble from Brain Tumour Research
hubs.ly/Q02ntP6g0
#IWD24

How could #AI and value-based care can influence healthcare delivery help create better care journeys? Find out in our latest interview >>> bit.ly/4ajBRMU

Attending #AACR24 in San Diego? Have a read of our news roundup to keep up-to-date with all the breaking stories from the conference! hubs.ly/Q02sh3tN0

Vaccination, revaccination, and coordination: What can we learn from ASCO’s latest set of healthcare guidelines? Find out on Oncology Central. hubs.ly/Q02rFSsR0

Explore opportunities for women in neuro-oncology, with insights from Sylvester Comprehensive Cancer Center's Macarena de la Fuente, who has been the co-chair of the Society for Neuro-Oncology’s Women and Diversity Committee: hubs.ly/Q02m_VCd0 SNO

.ASCO has released their latest recommendations on vaccinating cancer patients. Read all about how these guidelines could influence clinical decision making here >>> hubs.ly/Q02rFVxK0

Radka Stoyanova Sylvester Comprehensive Cancer Center is using AI to both detect glioblastoma tumor volume changes and build models to predict the response of a patient to a particular treatment. hubs.ly/Q02nkq1V0

From data infrastructure to patient empowerment, learn about the multifaceted approach to overcoming hurdles in value-based oncology care >>> bit.ly/4cSOdgK

Learn more about the eNRGy Phase I/II trial, a study investigating zenocutuzumab administered to patients with cancer caused by NRG1 gene fusions >>> bit.ly/4325eAE

eNRGy is a global Phase I/II trial currently recruiting patients with NRG1+ NSCLC, PDAC, or other solid tumors to assess zenocutuzumab, an investigational bispecific IgG1 antibody that inhibits NRG1-activated
HER2/HER3 oncogenic signaling bit.ly/3wLYBGc

What are the latest developments in diagnostic and therapeutic options for #PancreaticCancer patients? Find out in our interview with Mandana Kamgar (Medical College of Wisconsin) hubs.ly/Q02m-hYr0
#IWD2024 #InspireInclusion

Learn more about the eNRGy Phase I/II trial, a study investigating zenocutuzumab administered to patients with cancer caused by NRG1 gene fusions >>> bit.ly/3SWeH7P
@Future_OncolFSG

New research suggests a potential alternative to traditional FIT tests for colorectal cancer screening. With superior sensitivity, this next-generation stool DNA test offers improved detection. hubs.ly/Q02pRgCX0

Check out our latest interview, in which Mandana Kamgar (Medical College of Wisconsin) speaks about the importance of mentorship in her career and how she is looking to pay that forward to the next generation of #oncologists hubs.ly/Q02m-kvq0
#IWD2024 #InspireInclusion

How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression? Read our latest interview with Radka Stoyanova Sylvester Comprehensive Cancer Center to find out >>> hubs.ly/Q02nkqX10

🚀 Join our conversation with Karen Noblefrom Brain Tumour Research. Uncover the challenges and triumphs of her cancer research journey, with a spotlight on the innovative work in neuro-oncology >>> hubs.ly/Q02ntTyq0
#IWD24

This #InternationalWomensDay read Oncology Central’s interview with our Director of Research, Policy & Innovation, Karen Noble.

Karen discusses her career in oncology, developments in brain tumour research and the opportunities for women in STEM ➡️ bit.ly/3TsBHNi

eNRGy is a clinical trial testing zenocutuzumab administered to patients with cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here >>> bit.ly/431BH9V
@Future_OncolFSG

Discover the impactful role of mentors and role models in a neuro-oncologist's career. Read our exclusive with Macarena Ines de la Fuente (Sylvester Comprehensive Cancer Center) here: hubs.ly/Q02m_K4Y0